Novartis Terminates Sale of Sandoz US Generic Oral Solids, Dermatology Portfolio to Aurobindo in Mutual Agreement

April 2, 2020

In a mutual agreement with Aurobindo Pharma USA Inc., Novartis has terminated the agreement to sell the Sandoz US generic oral solids and dermatology businesses to Aurobindo. This decision was taken as approval from the U.S. Federal Trade Commission for the transaction was not obtained within anticipated timelines.

Sandoz will continue to operate its oral solids and dermatology business as part of the Sandoz US business.

Facebook Comments


We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free